Evidence map›Paper›PMID 40474968›Full record

ArticleFrontiers in pharmacology2025

Multi-omics and single-cell approaches reveal molecular subtypes and key cell interactions in hepatocellular carcinoma.

Xueqing Zou, Yongmei Wang, Mingyuan Luan, Yizheng Zhang

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. The authors respond to feedback onFrontiers in oncology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xueqing Zou *Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Yongmei Wang *Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Mingyuan LuanDepartment of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.
Yizheng ZhangDepartment of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hepatocellular carcinoma is a highly aggressive and heterogeneous malignancy with limited understanding of its heterogeneity. Methods: In this study, we applied ten multi-omics classification algorithms to identify three distinct molecular subtypes of HCC (C1-C3). To further explore the immune microenvironment of these molecular subtypes, we leveraged single-cell transcriptomic data and employed CIBERSORTx to deconvolute their immune landscape. Results: Among them, C3 exhibited the worst prognosis, whereas C1 and C2 were associated with relatively better clinical outcomes. Patients in the C3 group exhibited a high burden of copy number variations, mutation load, and methylation silencing. Our results revealed that compared to C1 and C2, C3 had a lower proportion of hepatocytes but a higher proportion of cholangiocytes and macrophages. Through analyses of hepatocyte, cholangiocyte, and macrophage subpopulations, we characterized their functional states, spatial distribution preferences, evolutionary relationships, and transcriptional regulatory networks, ultimately identifying cell subpopulations significantly associated with patient survival. Furthermore, we identified key ligand-receptor interactions, such as APOA1-TREM2 and APOA2-TREM2 in hepatocyte-macrophage crosstalk, and VTN-PLAUR in cholangiocyte-macrophage communication. Discussion: Finally, we employed machine learning methods to construct a prognostic model for HCC patients and identified novel potential compounds for high risk patients. In summary, our novel multi-omics classification of HCC provides valuable insights into tumor heterogeneity and prognosis, offering potential clinical applications for precision oncology.

Indexed as

hepatocellular carcinomamulti-omicsprecision oncologysingle-cell transcriptomicstumor heterogeneitytumor microenvironment

Identifiers

PMID40474968
PMCPMC12138379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.